Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-08-27
1998-06-16
Sayala, Chhaya D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 21, 530399, A61K 3818
Patent
active
057670790
ABSTRACT:
This invention is a method for the treatment of ophthalmic disorders. The method is suitable for treatment of a variety of disorders including macular holes, macular degeneration, and retinal detachment and tears, cataracts, and corneal and scleral injuries. The method entails application of an effective amount of Transforming Growth Factor-.beta. (TGF-.beta.) to the affected region.
REFERENCES:
patent: 4774322 (1988-09-01), Seyedin et al.
patent: 4939135 (1990-07-01), Robertson et al.
patent: 4983580 (1991-01-01), Gibson
patent: 5008240 (1991-04-01), Bentz et al.
patent: 5108989 (1992-04-01), Amento et al.
patent: 5411940 (1995-05-01), Nixon et al.
Gass, "Idiopathic senile macular hole--its early stages and pathogenesis" Arch. Ophthalmol. (1988) 108:629-639.
Feeny-Burns et al., "Aging human RPE: morphometric analysis of macular, equatorial, and peripheral cells" Invest. Ophthamol. Mol. Vis. Sci. (1984) 25:195-200.
MPS Group, "Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration" Arch. Ophthalmol. (1991) 109:1220-1231.
MPS Group, "Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration" Arch. Opthalmol. (1991) 109:1232-1241.
MPS Group, "Subfoveal neovascular lesions in age-related macular degeneration" Arch. Opthalmol. (1991) 109:1242-1257.
Sebag et al., "Diabetic retinopathy. Pathogenesis and the role of retina-derived growth factor in angiogenesis" Survey Ophthamol. (1986) 30:377-384.
Wiedemann, "Growth factors in retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal degeneration" Survey of Ophthalmol. (1992) 36(5):373-384.
Berritault et al., "Is there a ubiquitous growth factor in the eye?" Differentiation (1981) 18:29-42.
Chen et al., "Angiogenic activity of vitreous and retinal extract" Invest. Ophthamol. Vis. Res. (1980) 19:596-602.
D'Amore et al., "Endothelial cell mitogens derived from retina and hypothalamus: biochemical and biological similarities" J. Cell Physiol. (1984) 99:1545-1549.
Elstow et al., "Bovine retinal angiogenesis factor is a small molecule (molecular mass<600)" Invest. Ophthamol. Vis. Sci. (1985) 26:74-79.
Glaser et al., "The demonstration of angiogenic activity from ocular tissues" Ophthamol. (1980) 87:440-446.
Ruelius-Altemose e al., "Vascular endothelial cell growth: inhibition vs. stimulation" Invest. Ophthamol. Vis. Sci. (1985) 26(ARVO Suppl.):25.
Langer et al., "Isolation of a cartilage factor that inhibits tumor neovascularization" Science (1976) 193:70-71.
Raymond et al., "Isolation and identification of stimulatory and inhibitory cell growth factors in bovine vitreous" Exp. Eye Res. (1982) 34:267-286.
Lane et al., "Sjogren's syndrome" Harrison's Principles of Internal Medicine 12th Edition, McGraw-Hill Publishers, (1991) pp. 1449-1550.
Chiefetz et al., "The transforming growth factor-J system, a complex pattern of cross-reactive ligands and receptors" Cell (1987) 48:408-415.
Ikeda et al., "Human transforming growth factor type J2: production by a prostatic adenocarcinoma cell line, purification, and initial characterization" Biochem. (1987) 26:2406-2410.
Seyedin et al., "Cartilage-inducing factor-B is a unique protein structurally and functionally related to transforming growth factor-J" J. Biol. Chem. (1987) 262:1946-1949.
Derynck et al., "A new type of transforming growth factor-J, TGF-J3" EMBO J. (1987) 7(12):3737-3743.
Madisen et al., "Transforming growth factor-J2: cDNA cloning and sequence analysis" DNA (1988) 7(1):1-8.
Smiddy et al., "Transforming growth factor-J--a biological chorioretinal glue" Arch. Ophthalmol. (1989) 107:577-580.
Ignotz et al., "Transforming growth factor-J stimulates the expression of fibronectin in collagen and their incorporation into the extracellular matrix" J. Biol. Chem. (1986) 261(9):4337-4345.
Leschey et al., "Growth factor responsiveness of human retinal pigment eptithelial cells" Invest. Ophthamol. Vis. Sci. (1990) 31:839-846.
Plouet et al., "Transforming growth factor J-1 positively modulates the bioactivity of fibroblast growth factor on corneal endothelial cells" J. Cell Physiol. (1989) 141:392-399.
Connor et al., "Correlation of fibrosis and transforming growth factor-J type 2 levels in the eye" J. Clin. Invest. (1989) 83:1661-1666.
Ryan, S.J., Editor in Chief, Retina (1989) The C.V. Mosby Company, St. Louis, Judson, P.H., et al., "Macular Hole" Chapter 68, pp. 229-241.
LaVail, M.M. et al., Editors, Retinal Degeneration: Experimental and Clinical Studies (1985) Alan R. Liss, Inc., pp. 389-400.
Newsome, D.A., Editor, Retinal Dystrophies and Degenerations (1988) Raven Press, New York, Lewis, R.A., "Juvenile Heredity Macular Dystrophies" Chapter 8, p. 115.
Graycar et al., "Human transforming growth factor-J3: recombinant expression, purification, and biological activities in comparison with transforming growth factors-J1 and -J2" Molecular Endocrinology (1989) 3(12):1977-1986.
Lynch et al., "Growth factors in wound healing: single and synergistic effects on partial thickness porcine skin wounds" J. Clin. Invest. (1989) 84:640-646.
Glaser et al., "Transforming growth factor-J2 for the treatment of full-thickness macular holes" Paper presented in Oct. 1991, at the American Academy of Ophthalmology Annual Meeting, Anaheim, CA, pp. 1162-1173.
Glaser et al., "Induction of a `retinal patch` by transforming growth factor-J in the treatment of full thickness macular holes" Invest. Opthalmol. Vis. Sci. (1991) 32(4):713 (abstract No. 237).
Roberts, A.B. et al., "Peptide growth factors and their receptors I" Springer Verlag, Sporn et al., eds. Chapter 8, (1990).
Jampel et al., "Transforming growth factor-.beta. in human aqueous humor" Current Eye Research (1990) 9:963-970.
Tripathi et al., "Role of growth factors in the uveal tract of the eye as targeted to the development of new drugs" Drug Development Research (1991) 23:1-25.
Glaser Bert M.
Hanham Ann F.
Ksander George A.
Pharriss, deceased Bruce B.
Celtrix Pharmaceuticals Inc.
Sayala Chhaya D.
LandOfFree
Method of treating ophthalmic disorders using TGF -.beta. does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating ophthalmic disorders using TGF -.beta., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating ophthalmic disorders using TGF -.beta. will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1726091